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Abstract
Purpose Management of hypogonadism-induced osteo-
porosis in elderly men is still a challenge. We investigated
the short-term eVects of parathyroid hormone (PTH) treat-
ments on strength, micro-architecture, and mineral density
of trochanteric region of orchiectomized rat femur.
Methods Eight-month-old male Sprague–Dawley rats
(n = 44) were divided into two groups: (1) orchiectomized
(ORX) and (2) sham group. Twelve weeks after orchiec-
tomy, half of the orchiectomized animals were treated with
daily subcutaneously injected PTH (0.040 mg/kg/BW)
(ORX-PTH) for 5 weeks. The other half remained
untreated (ORX). The sham-operated group was divided
and treated in the same way (sham, sham-PTH). After
5 weeks, both femurs were excised for biomechanical and
histomorphometric analysis, trabecular measurements,
mineral content assessment, and immunoXuorescence anal-
ysis.
Results The femoral trochanteric strength after PTH treat-
ment was enhanced in the breaking test (ORX-Fmax =
158.7 N vs. ORX + PTH-Fmax = 202 N). StiVness of treated
ORX animals reached nearly the levels observed in
untreated sham rats. PTH therapy improved the trabecular
connectivity, width, and area (ORX-Tb.Ar = 47.79% vs.
ORX + PTH-Tb.Ar = 68.47%,  P < 0.05) in the proximal
femur. The treated rats showed signiWcantly improved min-
eral content in ashed femurs (ORX-mineral content =
43.73% vs. ORX + PTH-mineral content = 49.49%) when
compared to the untreated animals. A comparison of widths
of Xuorescence bands in cortical bone of the subtrochan-
teric cross-sections showed a signiWcant increase in opposi-
tions after the PTH therapy.
Conclusions Our  Wnding supports the hypothesis that
PTH therapy seems to be a rational therapy in patients with
hypogonadism induced bone loss and improves the bone
strength of trochanteric region of rat femur.
Keywords Hypogonadism · Osteoporosis · Parathyroid 
hormone · Trochanteric region
Introduction
One of the most important causes of osteoporosis in men
seems to be the change in level of sex steroid hormone in
older ages [1]. The testosterone deWciency induced osteo-
porosis in men develops later in life than in women but the
morbidity and mortality after osteoporotic fractures are
greater [1–3]. In addition to the primary hormone deW-
ciency in old men, the pharmacologic or surgical androgen
ablation treatment (AA) of prostate cancer increases the
risk of osteoporosis and fractures [4]. For these patients, the
British Columbia Cancer Agency recommended Guidelines
to arrange for bone mineral density (BMD) and begin of
osteoporosis prophylaxis if AA was to be used for 6 month
or longer [4].
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The recommended therapy modalities include both phar-
macologic and nonpharmacologic interventions [5, 6]. In
testosterone deWcient old men, the hormone replacement
therapy is discussed controversially and in patients with
prostate cancers after AA treatment even contraindicated
[7].
The positive anabolic eVect of parathyroid hormone
(PTH) on postmenopausal osteoporotic bone in women led
researchers in the last years to mention this hormone also
for treatment of osteoporosis in men [8, 9]. The key role
here plays the intermittent and not the continuous applica-
tion of the hormone [10, 11].
Rodents, like rat as animal model, have been established
for investigations in osteoporosis researches, especially
because the animals develop severe osteoporosis within
few weeks after gonadectomy [12].
In osteoporotic women and men, the femoral trochan-
teric fracture is one the most common fracture type. The
proximal part of femur in both rat and human contains a
grate content of trabecular and cortical bone with an intact
periosteal shell. For these reasons, this skeletal site has
gained a special meaning and a great importance in osteo-
porosis studies [10].
In the present work, we investigated the antiosteoporotic
potential of intermittent application of PTH on trochanteric
region of orchiectomized male rat.
Materials and methods
Experimental animals and substances
The experiments were carried out using 44 eight-month-old
male Sprague–Dawley rats. The animals were initially ran-
domized by weight (no signiWcant weight diVerences
between the groups) and divided into two groups: (1)
orchiectomized (ORX) and (2) sham groups (22 rats in each
group). Twelve weeks after orchiectomy, eleven of the
orchiectomized animals were treated with daily (7 days a
week) subcutaneously injected PTH (1–34) (0.04 mg/kg
body weight, one injection daily) (ORX-PTH) for 5 weeks.
The other half (11 rats) remained untreated (ORX). The
sham-operated group was divided and treated in the same
way (sham, sham-PTH with also 11 rats in each groups).
After 5 weeks, both femurs were excised for biomechani-
cal and histomorphometric analysis, trabecular measure-
ments, mineral content assessment, and immunoXuorescence
analysis. The operations were performed under intraperito-
neal ketamine (Medistar, Holzwickede, Germany) and xyla-
zine (Riemser, Greifswald-Insel Riems, Germany) anesthesia
(40 and 10 mg/kg body weight, respectively).
The experimental procedures were approved by the local
ethics commission under German animal protection law
(permission from 12/05/03, Az: 509.42502/01-53.03 Bez-
irkregierung Braunschweig). Twelve weeks after bilateral
ORX, the bilateral osteotomy and osteosynthesis (plate) of
tibia were performed. We started the drug treatments after
osteosynthesis, which continued for the next 5 weeks. After
5 weeks of drug therapy, the rats were euthanized and both
femurs were dissected free of soft tissue to be used for bio-
mechanical and histomorphometric tests. The results of
tibia osteotomy have recently been submitted.
During the treatment, the animals were subcutaneously
injected with four Xuorescent substances (Merck, Darms-
tadt, Germany) to mark the process of bone formation,
especially in the cortical surface. The following Xuorescent
agents injected were xylenol orange (90 mg/kg) on day 13,
calcein green (10 mg/kg) on day 18, alizarin red (30 mg/kg)
on day 24/26, and tetracycline (25 mg/kg) on day 35. The
results of the Xuorochrome labeling were analyzed in cross-
sections of femurs 15 mm distal from the femoral head in
the subtrochanteric region.
Biomechanical test
The biomechanical test was performed with our new break-
ing test as previously described [10]. Force was applied
with a ZWICK-testing machine, type 145660 Z020/TND
(Zwick/Roell, Ulm, Germany), from the lateral side of the
bone (vertically to the femoral length axis) to the greater
trochanter using a metallic stamp.
The range of assessment was from 2 N to 500 N. The
force was applied until the femur was broken in the tro-
chanteric region. Displacement and load were recorded,
and ultimate breaking strength (maximal load, Fmax (N))
and stiVness (slope of the linear part of the curve, represent-
ing elastic deformation, N/mm) have been calculated.
The testXpert software continuously recorded the force
applied until the femur was broken.
Radiographs in the anterior–posterior and lateral view
were performed for all left femurs tested in the study.
Cancellous and cortical bone histomorphometry
Sagittal sections (embedded in methylmethacrylate,
150 m thick) of the proximal femur were prepared using a
microtome (Leica, Sawmicrotom 1600). The region of
interest for the histomorphometric test was a frame between
the epiphyseal line and the femoral neck (2 mm distally).
The microradiographs of the sagittal sections of proximal
femurs were used to analyze the structural changes in the
trabecular surfaces.
A digitizing morphometric system was used to measure
bone histomorphometric parameters. The system consisted of
a microscope (Leica-System MZ 7.5), a digitizing pad cou-
pled to a PC and a morphometry program (Qwin software).World J Urol (2011) 29:529–534 531
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We assessed trabecular area (Tb.Ar), the number of tra-
becular nodes (N.Nd), trabecular connectivity (N.Nd/mm2),
and mean trabecular width (Tb.Wi) [13].
In our study, we measured the ratio between bone
diameter (B.Dm) and marrow diameter (Ma.Dm) in the
cross-sections 15 mm distal of the femoral head in the
subtrochanteric area. We assessed the B.Dm of the cross-
sections in the midline of the sections (ventro-dorsal axis)
and on the same line as the Ma.Dm as previously described.
The B.Dm/Ma.Dm ratio was used to compare changes in
the cortical width of the subtrochanteric region of the rat
femur among all groups.
Ashing
To determine the amount of mineralized bone, the right
femurs were mineralized at 750°C and weighed to the near-
est 10¡5 g. The femurs were weighed before and after ash-
ing. At the end of the experiment, the mineral content of
each bone was indicated as a percentage of the total weight
of the same femur (weight after ashing/weight before
ashing).
Statistics
The mean values of the diVerences between the study groups
in all of the comparative bioassays were assessed using one-
way ANOVA tests (Prism TM 4.0, Graph Pad, San Diego,
USA). P-values <0.05 were considered signiWcant.
Results
Changes in the body weight and mineral content
At the beginning of the study, no signiWcant weight diVer-
ences between all rats could be observed. At the end of the
trial, we could observe a clear increase in body weight
in both sham groups (sham: 75.6 g weight gain and
sham + PTH 7x/w: 59.3 g weight gain). At the end of the
study, the increase in the body weight led to signiWcant
diVerences between the both sham groups and the ORX
animals (ORX = 16.8 g weight gain, ORX + PTH 7x/w =
14.8 g weight gain) (Table 1).
The measured mineral content of left femurs showed sig-
niWcant higher results after PTH substitution in both
ORX + PTH 7x/w (49.49%) and sham + PTH 7x/w
(48.13%) compared to the ORX rats (43.73%).
Results of the histomorphometry test
After PTH therapy, there was a slightly increase concerning
trabecular connectivity (N.Nd/mm2) in the ORX + PTH 7x/
w animals (10.24) in comparison with the ORX rats (9.17).
The result, however, was not statistically signiWcant. The
rate of Tb.Ar and Tb.Wi was in both PTH-treated groups
(ORX + PTH 7x/w: TbAr: 68.47%, Tb.Wi: 14.93 mcm;
sham + PTH 7x/w: TbAr: 71.81%, Tb.Wi: 14.70 mcm) sig-
niWcantly higher than in ORX animals (Tb.Ar: 47.79%,
Tb.Wi: 11.23 mcm) (Table 1) (Fig. 1).
Table 1 Results of the body weights, biomechanical test, histomorphometric analysis, and bone mineral contents
The P-value of the diVerence between treated and untreated animals was calculated using a one-way ANOVA. P-values <0.05 were considered
signiWcant
ORX orchiectomy, B.Dm bone diameter, Ma.Dm marrow diameter
a P < 0.05 vs. ORX
Sham ORX ORX + PTH 7x/w Sham + PTH 7x/w
Mean STD Mean STD Mean STD Mean STD
Body weight
Before ORX (g) 650.9 74.89 613.6 54.83 662.7 79.92 631.9 55.30
At the end of trial (g) 726.5a 82.10 630.4 57.82 677.5 95.35 691.2 71.72
Weight gain (g) 75.6a 16.8 14.8 59.3a
Biomechanical changes
Maximal load (Fmax) (N) 212.8a 43.21 158.7 16.09 202.0 21.74 226.2a 51.70
StiVness (N/mm) 325.1a 101.1 215.1 44.13 320.9a 72.90 322.6a 81.51
Histomorphometry
Connectivity (N.Nd/mm2) 11.90a 1.76 9.17 1.81 10.24 1.73 11.56a 1.91
Trabecular area (Tb.Ar) (%) 63.39a 7.69 47.79 4.13 68.47a 8.22 71.81a 6.48
Trabecular width (mcm) 12.80 1.24 11.23 0.96 14.93a 2.61 14.70a 1.67
Trabecular nodes (N.Nd) 58.40a 12.49 39.58 9.13 49.00 11.66 52.25a 5.95
Ratio B.Dm/M.Dm 1.78a 0.09 1.64 0.1 1.95a 0.1 2.04a 0.11
Mineral content (after ashing) in left femurs (%) 44.45 1.21 43.73 1.90 49.49a 6.14 48.13a 0.88532 World J Urol (2011) 29:529–534
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Concerning the changes in the cortical surface of prox.
femur, the results of B.Dm/Ma.Dm ratio were in all groups
signiWcantly higher than in ORX animals (B.Dm/
Ma.Dm = 1.648). After PTH treatment, the animals reached in
ORX + PTH 7x/w (B.Dm/Ma.Dm = 1.952) group the level of
sham animals (B.Dm/Ma.Dm = 1.786) (Table 1) (Fig. 2).
The Xuorescence microscopy could qualitatively show that
after ORX there was only a very small apposition of Xuores-
cent agents. All animals showed after PTH therapy
(ORX + PTH 7x/w and sham + PTH 7x/w) a clearly higher
uptake of Xuorescent agents on the endosteal side of proximal
femur. In contrast, the inXuence of ORX and PTH treatment
thereafter remained at the periosteal side only minimal (Fig. 2).
Results of the breaking test
The mean level of maximum load (Fmax) in ORX rats was
158.7 N. With 202.00 N, the mean level of Fmax in
ORX + PTH 7x/w group was clearly higher in comparison
with the ORX group; however, the results, were not statisti-
cally signiWcant. In contrast, both the untreated and PTH-
treated sham groups (sham Fmax = 212.8 N; sham + PTH
7x/w Fmax = 226.2 N) showed signiWcantly higher maxi-
mum load compared to untreated ORX animals.
Concerning stiVness, the results were in all groups sig-
niWcantly higher than ORX rats (stiVness = 215.1 N/mm).
The best results reached both sham groups (sham stiVness =
325.1 N/mm; sham + PTH 7x/w stiVness = 322.6 N/mm)
(Table 1).
Discussion
Osteoporosis in men has gained more importance in the last
years [1,  3]. Although the concept of physiological low
testosterone level in elderly men, hormone ablation for
Fig. 1 The Wgure demonstrates the changes in trabecular structure of
distal (upper row) and proximal (lower row) femur of rats with and
without treatment of parathyroid hormone (PTH) for 5 weeks. The
inXuence of orchiectomy (ORX) on the named areas can clearly be
seen in ORX animals. The decrease in trabecular mass and architecture
could be prevented after PTH therapy
Fig. 2 The Wgure presents the inXuence of orchiectomy after 12 weeks
and the eVect of parathyroid application after 5 weeks. As demonstrated
above (“Results”), the decrease in marrow diameter (Ma.Dm) of the
cross-sections of proximal rat femur seems to be the mean cause for
higher B.Dm/Ma.Dm-results in both PTH-treated groups (upper row).
This means that the endosteal activity and the increase in bone forma-
tion are mainly localized at the endosteal side of the cortical surface.
The immunoXuorescence microscopy (lower row) conWrmed this factWorld J Urol (2011) 29:529–534 533
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therapy of advanced prostate carcinoma and treatment of
benign prostate hyperplasia by 5-reductase inhibitors, as
factors increasing osteoporosis are controversial, facing
men with manifest osteoporosis is rising in medical practice
[2, 7].
The main problem of the reduced bone mineral density is
the bone fracture, consecutive chronic skeletal pains, and
further disabilities. For osteoporosis in men, there are only
a few limited therapy options like bisphosphonate treatment
[1, 14]. In prostate hyperplasia or carcinoma after hormone
ablation therapy, the treatment of the hypogonadism-
induced osteoporosis is more complicated, because the
hormone replacement therapy in such conditions is contra-
productive or contraindicated. [7].
The continuous substitution of PTH, as known for exam-
ple in primary hyperparathyroidism, leads to an increase in
bone resorption and formation, but the Wrst component
(bone resorption) is here stronger activated than the second
(bone formation) [10, 15]. This imbalance at least, leads to
a decrease in bone mineral density. In the last decade, the
antiosteoporotic eVect of PTH is being more attractive. This
goal can be achieved only by an intermittent application of
the hormone [16]. The osteoanabolic eVect of PTH is
already established for treatment of severe postmenopausal
osteoporosis in women [11, 17].
Parathyroid hormone seems also to be an attractive alter-
native for treatment of hypogonadism-induced osteoporosis
in men [16].
The osteoanabolic eVect of PTH after intermittent appli-
cation can also be seen in bone metastasis of cancers like
prostate cancer [18]. It is well possible, that after PTH sub-
stitution not only the healthy bone cells (osteoblasts) but
also the pathologic cancer metastasis cells in bone can be
activated [19].
This fact maybe limits the use of PTH in such cases [18].
Here is the pre-therapeutic staging und evaluation of bone
metastasis must be performed. In our opinion, in cases of
the absence of bone metastasis, therapy with PTH can be an
interesting option.
One of the most important aspects in the therapy of oste-
oporosis in both men and women is the diVerent intensity of
eVect of antiosteoporotic drugs on diVerent skeletal sites
[10]. For example, it is known that the alendronate (bis-
phosphonate) seems to be more eVective and can better pre-
vent the vertebral body fractures compared to other skeletal
sites like proximal femur or proximal tibia [10, 20]. For this
reason, it is very important and necessary to investigate the
eVect of PTH on diVerent skeletal sites.
One of the most common fracture types in osteoporotic
men is the fracture of trochanteric region of femur [21]. In
our study, we investigated the short-term eVects of parathy-
roid hormone (PTH) on strength, micro-architecture, and
mineral density of trochanteric region of orchiectomized
rat. The main changes in the trabecular architecture were
due to the increase in trabecular width. In addition, the
increase in B.Dm/Ma.Dm ratio after PTH application indi-
cates after separate measuring of B.Dm and Ma.Dm in the
proximal femur that PTH mainly activates the endosteal
formation of cortex. The periosteal side of the cortical sur-
face remained nearly unaVected. This property was found,
in our work, due to a qualitative comparison of Xuorescence
apposition bands in the cross-sections of proximal femur of
rats.
At the end of the study, we observed only a minimally
weight gain in ORX rats in comparison with the sham
groups (PTH treated and untreated), although many studies
in female rats showed a clearly increase in weight after
ovariectomy (OVX) [10]. Orchiectomy and ovariectomy
seem to aVect the fat turn over diVerently. The exact mech-
anism of the weight changes in the diVerent male rats after
ORX is not exactly cleared.
Conclusion
In our study, the parathyroid hormone (PTH) was able to
treat the hypogonadism-induced bone loss of trochanteric
region of rat femur. After therapy with PTH, we observed
an increase in bone strength, trabecular micro-architecture,
and mineral content in rat femur. Our results show that
PTH seems to be a possible treatment option for hypogo-
nadism-induced osteoporosis in men, especially in diseases,
where testosterone replacement therapy is contraindicated.
Further studies, however, are necessary to prove the
eYcacy and safety of PTH for treatment of hypogonadism-
induced osteoporosis in men, especially after hormone
ablation therapy of malignant tumors like prostate cancer.
ConXict of interest The authors have no conXict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Rocchietti March M, Pisani D, Aliberti G (2009) Male osteoporo-
sis. Minerva Endocrinol 34:325–332
2. Guggenbuhl P (2009) Osteoporosis in males and females: is there
really a diVerence? Joint Bone Spine 76:595–601
3. Kamel HK (2005) Male osteoporosis: new trends in diagnosis and
therapy. Drugs Aging 22:741–748
4. Van Tongeren LS, Duncan GG, Kendler DL, Pai H (2009) Imple-
mentation of osteoporosis screening guidelines in prostate cancer
patients on androgen ablation. J Clin Densitom 12:287–291
5. Maricic M (2010) Intravenous zoledronic acid: what are the indi-
cations for male osteoporosis? Curr Osteoporos Rep 8:4–9534 World J Urol (2011) 29:529–534
123
6. Chlebowski RT, Tagawa T (2009) Early breast and prostate cancer
and clinical outcomes (fracture). Oncology (Williston Park)
23:16–20
7. Gomella LG (2009) EVective testosterone suppression for prostate
cancer: is there a best castration therapy? Rev Urol 11:52–60
8. Partridge NC, Li X, Qin L (2006) Understanding parathyroid hor-
mone action. Ann N Y Acad Sci 1068:187–193
9. Devogelaer JP, Boutsen Y, Manicourt DH (2010) Biologicals in
osteoporosis: teriparatide and parathyroid hormone in women and
men. Curr Osteoporos Rep 8:154–161
10. Tezval M, Stuermer EK, Sehmisch S, Rack T, Stary A, Stebener
M, Konietschke F, Stuermer KM (2010) Improvement of trochan-
teric bone quality in an osteoporosis model after short-term treat-
ment with parathyroid hormone: a new mechanical test for
trochanteric region of rat femur. Osteoporos Int 21:251–261
11. Matsumoto T, Shiraki M, Hagino H, Iinuma H, Nakamura T
(2006) Daily nasal spray of hPTH(1–34) for 3 months increases
bone mass in osteoporotic subjects: a pilot study. Osteoporos Int
17:1532–1538
12. Ishihara A, Sasaki T, Debari K, Furuya R, Kawawa T, Ramamur-
thy NS, Golub LM (1999) EVects of ovariectomy on bone mor-
phology in maxillae of mature rats. J Electron Microsc (Tokyo)
48:465–469
13. ParWtt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H,
Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry:
standardization of nomenclature, symbols, and units. Report of the
ASBMR Histomorphometry Nomenclature Committee. J Bone
Miner Res 2:595–610
14. Moro-Alvarez MJ, Cabrera JA (2010) Osteoporosis in men. Rev
Clin Esp 210:342–349
15. Eriksen EF (2002) Primary hyperparathyroidism: lessons from
bone histomorphometry. J Bone Miner Res 17(Suppl 2):N95–N97
16. Gabet Y, Kohavi D, Muller R, Chorev M, Bab I (2005) Intermit-
tently administered parathyroid hormone 1–34 reverses bone loss
and structural impairment in orchiectomized adult rats. Osteopo-
ros Int 16:1436–1443
17. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Regin-
ster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK et al
(2001) EVect of parathyroid hormone (1–34) on fractures and bone
mineral density in postmenopausal women with osteoporosis.
N Engl J Med 344:1434–1441
18. Quirosa Flores S, Varsavsky M, Valle Diaz De La Guardia F, Mi-
jan Ortiz JL, Munoz Torres M, Raya Alvarez E, Zuluaga Gomez
A (2010) Secondary hyperparathyroidism in advanced prostate
cancer. Endocrinol Nutr 57:100–104
19. Gomes RR Jr, Buttke P, Paul EM, Sikes RA (2009) Osteosclerotic
prostate cancer metastasis to murine bone are enhanced with in-
creased bone formation. Clin Exp Metastasis 26:641–651
20. Kaji H, Hisa I, Inoue Y, Naito J, Sugimoto T, Kasuga M (2009)
Analysis of factors aVecting increase in bone mineral density at
lumbar spine by bisphosphonate treatment in postmenopausal
osteoporosis. J Bone Miner Metab 27:76–82
21. Woratanarat P, Kijkunastian C, Wajanavisit W, Suppaphol S,
Woratanarat T, Rajatanavin R, Boonyaratavej N, Suriyawongpai-
sal P (2009) A comparative study of risk factors of femoral neck
and intertrochanteric fracture in Thai men. J Med Assoc Thai
92(Suppl 6):S165–S171